- Previous Close
0.0550 - Open
0.0545 - Bid 0.0555 x 10000000
- Ask 0.0735 x 10000000
- Day's Range
0.0545 - 0.0555 - 52 Week Range
0.0050 - 0.0950 - Volume
50,000 - Avg. Volume
781 - Market Cap (intraday)
2.859B - Beta (5Y Monthly) --
- PE Ratio (TTM)
∞ - EPS (TTM)
0.0000 - Earnings Date Apr 29, 2025 - May 5, 2025
- Forward Dividend & Yield 0.00 (3.11%)
- Ex-Dividend Date May 29, 2024
- 1y Target Est
--
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business; and E-health products. It operates Mitrasana Clinics, a health care service. In addition, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. PT Kalbe Farma Tbk. was incorporated in 1966 and is headquartered in Jakarta, Indonesia.
www.kalbe.co.id--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: LCLA.F
View MorePerformance Overview: LCLA.F
Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is IDX COMPOSITE (^JKSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LCLA.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LCLA.F
View MoreValuation Measures
Market Cap
2.86B
Enterprise Value
2.63B
Trailing P/E
15.00
Forward P/E
14.06
PEG Ratio (5yr expected)
1.29
Price/Sales (ttm)
1.49
Price/Book (mrq)
2.12
Enterprise Value/Revenue
1.53
Enterprise Value/EBITDA
10.82
Financial Highlights
Profitability and Income Statement
Profit Margin
9.93%
Return on Assets (ttm)
9.03%
Return on Equity (ttm)
13.61%
Revenue (ttm)
32.63T
Net Income Avi to Common (ttm)
3.24T
Diluted EPS (ttm)
0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
4.72T
Total Debt/Equity (mrq)
2.28%
Levered Free Cash Flow (ttm)
2.24T